2:34 PM
Jul 12, 2018
 |  BC Extra  |  Clinical News

Oyster Point's nasal spray meets in Phase IIb for dry eye

Oyster Point Pharma Inc. (Princeton, N.J.) said its OC-02 nasal spray met the primary endpoints in the U.S. Phase IIb PEARL trial to treat dry eye disease. CEO Jeffrey Nau told BioCentury Oyster Point plans to begin a Phase III trial in 3Q19, with an NDA submission slated for 2020.

A potential first-in-class treatment, OC-02 is a nicotinic acetylcholine receptor...

Read the full 279 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >